UK markets closed
NIKKEI 225
38,471.20 -761.60 (-1.94%) HANG SENG
16,248.97 -351.49 (-2.12%) CRUDE OIL
85.35 -0.01 (-0.01%) GOLD FUTURES
2,399.40 -8.40 (-0.35%) DOW
37,798.97 +63.86 (+0.17%) Bitcoin GBP
51,386.04 +606.68 (+1.19%)
Propanc Biopharma, Inc. (PPCB)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 03:54PM EDT
| Previous close | 0.0014 |
| Open | 0.0014 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0013 - 0.0016 |
| 52-week range | 0.0001 - 0.2625 |
| Volume | |
| Avg. volume | 3,546,070 |
| Market cap | 67,788 |
| Beta (5Y monthly) | 1.69 |
| PE ratio (TTM) | 0.01 |
| EPS (TTM) | 0.2400 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WirePropanc Biopharma Receives Certificate of Grant for "Composition of Proenzymes for Cancer Treatment" Patent from European Patent Office
MELBOURNE, Australia, April 16, 2024--The PRP dosing patent is an important part of our IP portfolio, as we seek to protect our novel invention and create future value for our shareholders
Business WirePropanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing
MELBOURNE, Australia, April 08, 2024--Mr. Nathanielsz appeared on a show with Mr. Joel Block, a weekly podcast on killer business strategies and how the best leaders make them work
Business WirePropanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study
MELBOURNE, Australia, February 22, 2024--The compassionate use study results highlight clinical effects studied in 46 patients with advanced metastatic cancers of different origin
© 2024 Yahoo. All rights reserved.